Figure 2 | Scientific Reports

Figure 2

From: Exome sequencing identifies novel compound heterozygous IFNA4 and IFNA10 mutations as a cause of impaired function in Crohn’s disease patients

Figure 2

ELISA analysis of serum IFNA4 and IFNA10 levels. A Wilcoxon two-sample test was performed to evaluate the differences between 47 CD patients and 95 healthy controls. Comparison of the serum IFNA4 level between CD patients and healthy controls (A) and between wild-type and mutant alleles in CD patients and healthy controls (B) N indicates normal healthy control. Comparison of the serum IFNA10 level between CD patients and healthy controls (C) and between wild-type and mutant alleles in CD patients and healthy controls (D). (E-F) Comparison of serum IFNA4 and IFNA10 between IFN single-subtype and dual-subtype variants in CD patients, respectively (*P < 0.05).

Back to article page